Key Takeaways
- Neuracle’s NEO brain-computer interface (BCI) received swift regulatory approval in China, outpacing competitors like Neuralink.
- NEO’s less invasive design, coupled with China’s strong support for BCI technology, facilitated quicker approval and integration into health systems.
- This development marks a significant milestone for the BCI industry, enabling large-scale production and clinical application in China, benefiting patients with spinal cord injuries.
NEO’s Quick Approval and Its Impact on the BCI Industry
Neuracle’s brain-computer interface (BCI), known as NEO, achieved regulatory approval in China, making it the first of its kind to gain such recognition, surpassing competitors like Neuralink, founded by Elon Musk. As of October 2023, Neuracle conducted 36 clinical trials with NEO, notably involving one patient named Dong. A significant number of these trials took place in just a few months in 2025, with a pivotal preprint paper detailing one of the initial in-person trials released last July.
One contributing factor to NEO’s expedited approval is its less invasive design. Unlike Neuralink’s N1 brain chip, which requires direct penetration into the brain’s cortex, NEO employs a design where its eight sensors are strategically placed on the brain’s protective membrane. This design minimizes the risks typically associated with brain surgery, such as hemorrhage, glial scarring, and signal degradation, according to BCI researcher Avinash Singh from the University of Technology Sydney.
Additionally, NEO benefited from China’s robust support for its BCI industry, placing it on an expedited regulatory pathway. This is in stark contrast to the lengthy approval process typically seen with the U.S. Food and Drug Administration, which can span several years.
The approval of NEO holds significant implications for the global BCI sector, according to Wang Shouyan, a neuroscientist at Fudan University. Historically, BCI research and development has been largely confined to laboratory settings. The recent approval indicates a readiness for large-scale manufacturing and clinical application within China.
For individuals like Dong, the significance of NEO extends beyond the technological innovation. He expressed hope that the BCI could aid not only himself but countless others in China suffering from spinal cord injuries. “It will bring them hope and change their lives,” he remarked.
Following the approval, the Chinese government began integrating NEO into its health insurance system by assigning it a unique code. This initiative will enable eligible patients to subsidize part of the device’s cost, enhancing accessibility.
As a result of government policy support and financial backing, the growth trajectory of China’s BCI industry is expected to accelerate. The latest five-year plan of China, unveiled on the same day as NEO’s approval, identifies BCI as a crucial sector, alongside quantum technology and humanoid robotics, vital for the country’s technological competitiveness.
Several Chinese startups, including NeuroXess and StairMed, have been active in the BCI domain for years, laying a strong foundation for future advancements. Information scientist Meicen Sun from the University of Illinois Urbana-Champaign noted that China’s commitment to leading the global BCI field is influenced by the accomplishments of these pioneering companies.
Overall, the landscape of brain-computer interfaces in China is poised for transformation, driven by innovative technologies and governmental support, potentially improving the quality of life for many patients.
The content above is a summary. For more details, see the source article.